LAS VEGAS and HAWTHORNE, N.Y., Oct. 13 /PRNewswire-FirstCall/ -- Skinvisible Pharmaceuticals, Inc. a wholly owned subsidiary of Skinvisible, Inc (Website: www.skinvisible.com) and the Cosmetic Business Unit (Rona) of EMD Chemicals Inc. (Website: www.emdchemicals.com), an affiliate of Merck KGaA, Darmstadt, Germany are pleased to announce they have signed an exclusive worldwide sales, collaboration and distribution agreement for the personal care market involving Skinvisible's patented polymer-based topical delivery vehicle, Invisicare(R). Under the terms of the agreement, EMD will promote this patent-protected product to the global personal care industry. In addition to the distribution agreement EMD and Skinvisible have reached an agreement whereby EMD would have a future right to acquire an equity interest in Skinvisible.
(Logo: http://www.newscom.com/cgi-bin/prnh/20030416/LAW068LOGO )
The Invisicare(R) polymer delivery vehicle is specially formulated to carry water insoluble active ingredients in water-based systems without the use of alcohol, silicones, petrolatum or other organic solvents. Invisicare(R) is also well-suited to carry water soluble actives and because of its unique functionality results in the release of such ingredients by controlled diffusion into the skin. This patented process which combines hydrophilic and hydrophobic polymers results in stable complexes with improved skin adhesion, barrier protection and moisturizing properties.
Mr. Dan Giambattisto, Sr. Business Development Manager of EMD's Cosmetic Business Unit states, "This partnership will provide our customers with a novel means of increasing the effectiveness of their active ingredients and enables EMD to become a more comprehensive supplier of value-added products and services for the personal care industry."
This marketing agreement gives Skinvisible and its Invisicare(R) line instant worldwide exposure, something that was not previously feasible," says Skinvisible President, Mr. Terry Howlett.
About EMD Chemicals Inc.;
EMD Chemicals Inc. represents the North American specialty chemical extension of Merck KGaA, Darmstadt, Germany. As an international company with 1,150 employees and revenues of more than $350 million, EMD Chemicals focuses on specialty chemicals for pharmaceutical, biotech, cosmetic, automotive, plastics and other industrial applications.
About Merck KGaA, Darmstadt, Germany;
Merck is a global pharmaceutical and chemical company with sales of EUR 5.9 billion in 2004, a history that began in 1668, and a future shaped by 28,600 employees in 54 countries. The former U.S. subsidiary, Merck & Co., has been completely independent of the Merck Group since 1917.
About Skinvisible Pharmaceuticals, Inc.;
Headquartered in Las Vegas, Nevada, Skinvisible Pharmaceuticals, Inc. is a research and development company that has formulated and patented innovative polymer delivery system technology and compositions for topical skin applications. Skinvisible's primary marketing and sales objective is to license its technology and sell its trademarked polymer delivery vehicles to established dermatological, cosmetic, skincare and pharmaceutical manufacturers.
This press release contains "forward looking" statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934 as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports that will be on file with the US Securities and Exchange Commission (including but not limited to the report on Form 10QSB for the quarter ending June 30, 2005).
Photo:
http://www.newscom.com/cgi-bin/prnh/20030416/LAW068LOGOAP Archive:
http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comSkinvisible Pharmaceuticals, Inc.
CONTACT: Corporate, T. Howlett of Skinvisible, Inc., +1-702-433-7154, orfax, +1-702-433-7192, terry@skinvisible.com; or Media, Tommi Hanley ofThompson Lloyd Communications, +1-250-860-9959, tommi.tlc@shaw.ca, forSkinvisible Pharmaceuticals, Inc.